FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - February 11, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Qué saber al buscar información sobre el cáncer en línea: perspectiva... August 11, 2022 A tribute to Dame Valerie Beral October 13, 2022 Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... March 26, 2025 How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 Load more HOT NEWS How I Learned to Advocate for Myself During Cancer: “Your Stories”... 15% of People With Lung Cancer Have an Inherited Mutation for... FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma Tailored Psychotherapy Eases Depression in People with Advanced Cancer
